journal article·2019-12-04Open access

mPEG-icariin nanoparticles for treating myocardial ischaemia

Yongqiang Zheng, Lingli Lu, Zhengli Yan, Sufang Jiang, Shanyi Yang, Yingzi Zhang, Kangwei Xu, Chunlian He, Xiaojun Tao, Qiufang Zhang

Abstract

Icariin (ICA), a major active ingredient from Chinese medicine, has unique pharmacological effects on ischaemic heart disease. However, its hydrophobic property limits its administration and leads to poor efficacy. This work aimed to change its hydrophobic property and improve the treatment efficacy. We designed a new nano-drug to increase the ICA delivery. ICA was modified with hydrophilic polyethylene glycol monomethyl ether (mPEG) by a succinic anhydride linker to form a polyethylene glycol-icariin (mPEG-ICA) polymer. The structure of this polymer was identified by Fourier transform infrared spectroscopy and nuclear magnetic resonance spectroscopy. The content of ICA in the polymer was 32% as detected by ultraviolet spectrophotometry. mPEG-ICA nanoparticles, of 143.3 nm, were prepared by the dialysis method, and zeta potential was 0.439 mV by dynamic light scattering. The nanoparticles had a spherical shape on transmission electron microscopy. In media with pH 7.4 and 6.8, ICA release from mPEG-ICA nanoparticles after 72 h was about 0.78% and 64.05%, respectively, so the ICA release depended on the release media pH. On MTT and lactate dehydrogenase activity assay, mPEG-ICA nanoparticles could reduce cell damage induced by oxgen-glucose deprivation. Hoechst 33258 staining and TUNEL and AnnexinV-FITC/PI double staining showed that ICA nanoparticles could increase the activity of H9c2 cardiomyocytes under oxgen-glucose deprivation conditions by decreasing apoptosis. ICA modified by hydrophilic mPEG could improve its efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Medicinal Plant Pharmacodynamics Research · Cancer-related molecular mechanisms research · Natural product bioactivities and synthesis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology, Laboratory of Chinese Herbal Pharmacology, Biomedical Research Institute, Hubei University of Medicine

Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University

Funding

the Health and Family planning commission of Hunan Province research project · National Natural Science Foundation of China · Hubei Province health and family planning scientific research project · Changsha science and Technology Bureau

References (48)

Show source-provided references
1. 10.1016/j.jacc.2012.11.00210.1016/j.jacc.2012.11.002 ↗
2. Huang H, Yao QY, Xia EH, et al. Metabolomics and transcriptomics analyses reveal nitrogen influences on the accumulation of flavonoids and amino acids in young shoots of tea plant (Camellia sinensis L.) associated with tea flavor. J Agric Food Chem 2018;17:158–170.
3. 10.1055/s-2005-87312610.1055/s-2005-873126 ↗
4. Liu HJ, Liu XY, Jing DB. Icariin induces the growth, migration and osteoblastic differentiation of human periodontal ligament fibroblasts by inhibiting Toll-like receptor 4 and NF-κB p65 phosphorylation. Mol Med Rep. 2018;18:3325–3331.
5. Liu SY, Wu HJ. Research progress of icariin pharmacologic action. Med Recapit 2009;6:909–912.
6. 10.1007/s00198-017-4255-110.1007/s00198-017-4255-1 ↗
7. Zhang Y, Sai LI, Ding XS. Effect of icariin on the vasodilation function of renal artery in diabetic nephropathy rats. Pharm Clin Res. 2016;3:209–211.
8. 10.1002/ptr.373310.1002/ptr.3733 ↗
9. Xu S, Yu J, Zhan J, et al. Pharmacokinetics, tissue distribution, and metabolism study of icariin in rat. Biomed Res Int. 2017;9:4684–4702.
10. Jia LL, Yuan D, Wang HW, et al. The pharmacological research advance of icariin. Prog Mod Biomed. 2010;20:3976–3979.
11. Gao M, Ma FF, Wu SH, et al. Research advance in the pharmacological effects of icariin. Med Plant. 2013;1:79–82.
12. 10.1007/s00289-015-1534-x10.1007/s00289-015-1534-x ↗
13. 10.1016/j.colsurfb.2015.12.02710.1016/j.colsurfb.2015.12.027 ↗
14. 10.1016/j.lfs.2015.01.00610.1016/j.lfs.2015.01.006 ↗
15. 10.1002/adhm.20130061710.1002/adhm.201300617 ↗
16. 10.1002/prot.2238310.1002/prot.22383 ↗
17. Shao CY, Tu JS. Design strategy of antitumor polymer micelles. Pharm Clin Res. 2010;18:286–290.
18. 10.1517/17425247.2011.56655210.1517/17425247.2011.566552 ↗
19. 10.2165/00063030-200115070-0000110.2165/00063030-200115070-00001 ↗
20. 10.3109/21691401.2016.113849210.3109/21691401.2016.1138492 ↗
21. 10.2478/v10007-007-0050-410.2478/v10007-007-0050-4 ↗
22. 10.2147/IJN.S7346210.2147/IJN.S73462 ↗
23. 10.1002/352760183X10.1002/352760183X ↗
24. 10.2174/13892001079111082710.2174/138920010791110827 ↗
25. 10.1586/14737159.5.6.89310.1586/14737159.5.6.893 ↗
26. Zhang H, Zhang C, Ping Q. Research and application of polymeric micelles as drug carriers. Prog Pharm Sci 2002;6:326–329.
27. 10.1016/j.nantod.2014.04.00810.1016/j.nantod.2014.04.008 ↗
28. 10.1021/bc100070g10.1021/bc100070g ↗
29. 10.1039/C6PY00449K10.1039/C6PY00449K ↗
30. 10.1007/s11426-012-4528-710.1007/s11426-012-4528-7 ↗
31. 10.1002/adfm.20050061110.1002/adfm.200500611 ↗
32. 10.1163/092050611X57541410.1163/092050611X575414 ↗
33. 10.1016/j.tetlet.2010.07.14610.1016/j.tetlet.2010.07.146 ↗
34. 10.1016/j.carres.2007.10.02510.1016/j.carres.2007.10.025 ↗
35. 10.1016/S0039-9140(97)00288-910.1016/S0039-9140(97)00288-9 ↗
36. 10.1074/jbc.M30305120010.1074/jbc.M303051200 ↗
37. 10.1016/0014-4827(77)90089-110.1016/0014-4827(77)90089-1 ↗
38. 10.1007/BF0127057610.1007/BF01270576 ↗
39. 10.1155/2017/468496210.1155/2017/4684962 ↗
40. 10.1002/jcb.2425910.1002/jcb.24259 ↗
41. 10.3109/10731199.2011.59249410.3109/10731199.2011.592494 ↗
42. 10.2174/138161282166615081710463510.2174/1381612821666150817104635 ↗
43. 10.1002/advs.20170082110.1002/advs.201700821 ↗
44. 10.3390/nano807048610.3390/nano8070486 ↗
45. Wu B, Feng JY, Yu LM, et al. Icariin protects cardiomyocytes against ischemia/reperfusion injury by attenuating sirt1-dependent mitochondrial oxidative damage. Br J Pharmacol. 2018;18:14457–14496.
46. 10.3109/10731199.2010.49458110.3109/10731199.2010.494581 ↗
47. 10.1074/jbc.M109.01267410.1074/jbc.M109.012674 ↗
48. 10.1186/s12935-017-0410-110.1186/s12935-017-0410-1 ↗